Journal Information
Vol. 30. Issue 6.
Pages 282-286 (June - July 1994)
Share
Share
Download PDF
More article options
Vol. 30. Issue 6.
Pages 282-286 (June - July 1994)
Full text access
Receptor para el factor de crecimiento epidérmico en el cáncer de pulmón no microcítico
Epidermic growth factor receptor in non-small cell carcinoma of the lung
Visits
4546
M. Díeza,*, M.L. Maestrob, A. Torresc, F. Hernandoc, M.D. Ortegad, J.A. García-Asenjoe, A. Picardoc, J.M. Mugüerzaa, A. Sánchez-Pernautec, J.L. Balibreac
a Servicio de Cirugía General. Hospital Universitario. Alcalá de Henares. Madrid
b Servicios de Medicina Nuclear, Hospital Universitario San Carlos. Madrid
c Servicios de Cirugía General II, Hospital Universitario San Carlos. Madrid
d Servicios de Bioquímica Clínica, Hospital Universitario San Carlos. Madrid
e Servicios de Anatomía Patológica.Hospital Universitario San Carlos. Madrid
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

En este trabajo se estudia la concentración de receptor para el factor epidérmico de crecimiento (EGFr) en el cáncer de pulmón no microcítico (CPNM) y se analiza la relación con factores anatomopatológicos y clínicos de estas neoplasias. La concentración de EGFr en 62 muestras de tejido tumoral fue 9,9±14 fmol/mg, superior a la encontrada en 14 muestras de tejido procedente de neumotórax espontáneo (3,9±3,6 fmol/ mg) (p=0,005). La concentración de EGFr en el tejido pulmonar no afectado por la neoplasia fue 6,5±10 fmol/mg. En 21 (33%) casos de CPNM la concentración fue superior al nivel adoptado como umbral de normalidad (10 fmol/mg). El valor de EGFr fue superior en los carcinomas epidermoides que en los otros tipos histológicos (p=0,042). No se detectó relación significativa entre nivel de EGFr y estadio TNM, grado de diferenciación e índice mitótico. La probabilidad de permanecer libre de recidiva tumoral y la supervivencia global a los 24 meses entre los sujetos que presentaron una concentración de EGFr en el tumor inferior a 10 fmol/mg fueron 34 y 40%, respectivamente. Dichas tasas para los pacientes con valores superiores al dintel fueron 20% (p=0,32) y 25% (p=0,26), respectivamente. Los resultados parecen indicar que el estudio de la concentración de EGFr, de forma aislada, no implica consecuencias prácticas importantes para el manejo clínico de los pacientes con CPNM intervenidos quirúrgicamente. La expresión de EGFr en CPNM se comporta como un marcador del grado de diferenciación, con implicaciones pronósticas derivadas de su relación con otros factores asociados.

In this study we determined the concentration of epidermic growth factor receptors (EGFr) in non-small cell carcinoma of the lung (NSCCL) and analyzed its relation to the anatomical, pathological and clinical factors of these neoplasms. The concentration of EGFr in 62 tumor tissue samples was 9.9±14 fmol/mg, higher than that found in 14 tissue samples from cases of spontaneous pneumothorax (3.9±3.6 fmol/mg) (p=0.005). EGFr concentration in lung tissue with no signs of neoplasm was 6.5±10 fmol/mg. In 21 (33%) cases of NSCCL the concentration exceded the normal threshold of 10 fmol/mg. EGFr concentration was higher in cases of epidermoid carcinoma than in other tissue samples (p=0.042). No significant association was found between EGFr levels and status of tumor node metastasis, degree of differentiation and mitotic index. The probability of remaining free of tumor recurrence and of survival after 24 months among patients whose tumoral EGFr concentration was below 10 fmol/mg was 34 and 40%, respectively. The rates for patients with concentrations that exceeded the threshold were 20% (p=0.32) and 25% (p=0.26), respectively. The results seem to indicate that the study of EGFr concentration alone does not yield practically important information for the management of patients with NSCCL who have undergone surgery. The concentration of EGFr marks degree of differentiation in NSCCL and has prognostic implications derived from its association with other factors.

Full text is only aviable in PDF
Bibliografía
[1.]
D.N. Carney.
Lung Cancer Biology.
Eur J Cancer, 27 (1991), pp. 369-372
[2.]
A.W. Burgess.
Epidemial growth factor and transforming growth factor alfa.
Br Med Bull, 45 (1989), pp. 401-424
[3.]
G. Carpenter, J.G. Zendegui.
Epidemial growth factor, its receptor and related proteins.
Exp Cell Res, 164 (1986), pp. 1
[4.]
E. Spitzer, R. Grosse, D. Kunde, H.E. Schmidt.
Growth of mammary epithelial cells in breast cancer biopsies correlated with EGF binding.
Int J Cancer, 39 (1987), pp. 279
[5.]
J.R.C. Sainsbury, J.R. Farndon, G.K. Needham, A.J. Malcom, A.L. Harris.
Epidemial growth factor receptor status as predictor of early recurrence and of death from breast cancer.
Lancet, 1 (1987), pp. 1.398-1.402
[6.]
R.E. Moe, K.S. Moe, P. Porter, A. Gown, G. Ellis, D. Tapper.
Expression of Her-2/neu oncogene protein product and epidermal growth factor receptors in surgical specimens of human breast cancers.
Am J Surg, 161 (1991), pp. 580-583
[7.]
WHO.
Histological Typing of Lung Tumors.
2.a, Ginebra, (1981),
[8.]
D. Carter, J.L. Eggleston.
Tumors of the lower respiratory tract.
Atlas of tumor pathology. Serono Series. Pt 17, AFIP, (1980),
[9.]
W.J. Mooi, B.J. Addis.
Carcinoma of the Lung.
The Lungs. Edimburg, pp. 341-372
[10.]
C.F. Mountain.
A new International Staging system for lung cancer.
Chest, 89 (1986), pp. 225-231
[11.]
H. Dazzi, P.S. Hasleton, N. Thatcher, D.M. Barnes, S. Wilkes, R. Swindell, R.A.M. Lawson.
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cáncer. Use of archival tissue and correlation of RGF-R with histology, tumor size, node status and survival.
Br J Cancer, 59 (1989), pp. 746-749
[12.]
F.J. Handler, B.W. Ozanne.
Human squamous cell lung cancers express increased epidermal growth factor receptors.
J Clin Invest, 74 (1984), pp. 647-651
[13.]
R. Dittadi, M. Gion, V. Pagan, A. Brazzale, O. Del Maschio, A. Bargossi, A. Busetto, G. Bruscagnin.
Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue.
Br J Cancer, 64 (1991), pp. 741-744
[14.]
V. Gorgoulis, D. Aninos, P. Mikou, P. Kanavaros, A. Karameris, J. Joardanoglou, A. Rasidakis, M. Veslemes, B. Ozanne, D.A. Spandidos.
Expression of EGF. TGF-alpha and EGFR in squamous cell lung carcinomas.
Anticancer Res, 12 (1992), pp. 1.183-1.187
[15.]
M.S. Berger, W.J. Gullick, C. Greenfield, S. Evans, B.J. Addis, M.D. Waterfíeld.
Epidermal growth factor receptors in lung tumors.
J Pathol, 152 (1987), pp. 297
[16.]
D. Veale, T. Asheroft, C. Marsh, G.J. Gigson, A.L. Harris.
Epidermal growth factor receptors in non-small cell lung cancer.
Br J Cancer, 55 (1987), pp. 513-516
[17.]
D.L. Hwang, Y.C. Tay, S.S. Lin, A. Lev-Ran.
Expression of epidermal growth factor receptors in human lung tumors.
Cancer, 58 (1986),
[18.]
D. Veale, N. Kerr, G.J. Gigson, A.L. Harris.
Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer.
Cancer Res, 49 (1989), pp. 1.313-1.317
[19.]
S. Nicholson, J. Richard, C. Sainsbury.
Epidermal growth factor receptor: results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.
Br J Cancer, 83 (1991), pp. 146-150
[20.]
C.R. Divgi, S. Welt, S. Kris, F.X. Real, S.D. Yeh, R. Gralla, B. Merchant, S. Schweighart, M. Unger, S.M. Larson, I. Phase.
and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.
J Natl Cancer Inst, 83 (1991), pp. 97-104
Copyright © 1994. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?